Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
It’s not pedantic when the original commenter I was responding to was saying that traditional weight loss wasn’t a permanent cure, for the same reason that gol1s aren’t a cure… but then framing them as a cure.
They’re not permanent and they do have risks associated with them (pancreatitis and GI tract issues iirc,)